Advertisement

Magen-Darm-Mittel und Lebertherapeutika

  • Joachim Mössner

Zusammenfassung

Bedeutsamste Gruppe der Magen-Darm-Mittel sind wie in den vergangenen Jahren unverändert mit großem Abstand vor allen anderen Präparategruppen die Protonenpumpeninhibitoren. H2-Rezeptorenblocker werden mit weiter fallender Tendenz, eingesetzt. Die Verordnung der meisten anderen Magen-Darm-Mittel blieb im Wesentlichen unverändert. Bei Medikamenten gegen chronisch-entzündliche Darmkrankheiten ist wie 2012 ein leichter Anstieg zu verzeichnen. Kleinere Verordnungsvolumina entfallen auf Prokinetika, Lebertherapeutika, Pankreasenzyme, Spasmolytika, Antidiarrhoika und Laxantien.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (2009): Arzneiverordnungen. Empfehlungen zur rationalen Pharmakotherapie. 22. Auflage, Medizinische Medien Informations GmbH (MMI) Neu-Isenburg, S. 823–835Google Scholar
  2. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362:1071–1081PubMedCrossRefGoogle Scholar
  3. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. The Lancet 371:651–659CrossRefGoogle Scholar
  4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528CrossRefGoogle Scholar
  5. Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O’Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR, Dunitz J, Murray FT (2006) Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 32:258–263PubMedCrossRefGoogle Scholar
  6. Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bonnot-Marlier S (2005) Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 21:805–812PubMedCrossRefGoogle Scholar
  7. Bouras EP, Scolapio JS (2004) Gastric motility disorders: management that optimizes nutritional status. J Clin Gastroenterol 38: 549-557.Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008): A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358:2344–2354Google Scholar
  8. Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358:2344–2354PubMedCrossRefGoogle Scholar
  9. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110PubMedCrossRefGoogle Scholar
  10. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352:238–244PubMedCrossRefGoogle Scholar
  11. Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:93–101PubMedCentralPubMedCrossRefGoogle Scholar
  12. Cornberg M, Höner zuSC, Maasoumy B, Manns MP (2014) Neue direkt antivirale Medikamente zur Behandlung der chronischen Hepatitis C 2014. Internist (Berl) 55:390–400CrossRefGoogle Scholar
  13. Depta JP, Bhatt DL (2012) Antiplatelet therapy and proton pump inhibition: cause for concern? Curr Opin Cardiol 27:642–650PubMedCrossRefGoogle Scholar
  14. DeVault KR, Castell DO; American College of Gastroenterology (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100:190–200PubMedCrossRefGoogle Scholar
  15. De Vrese M, Marteau PR (2007): Probiotics and prebiotics: effects on diarrhea. J Nutr 137 (3 Suppl 2): 803S–811SGoogle Scholar
  16. Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L (2012) Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction – a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 35:48–55PubMedCentralPubMedCrossRefGoogle Scholar
  17. Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J (2014) Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 146:110–118PubMedCrossRefGoogle Scholar
  18. Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Bornschein J, Götze O, Höhne W, Kist M, Koletzko S, Labenz J, Layer P, Miehlke S, Morgner A, Peitz U, Preiss JC, Prinz C, Rosien U, Schmidt WE, Schwarzer A, Suerbaum S, Timmer A, Treiber G, Vieth M (2009): S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit.” Z Gastroenterol 47: 68–102Google Scholar
  19. Gatta L, Vakil N, Vaira D, Scarpignato C (2013): Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ; 347: f4587. doi: 10.1136/bmj.f4587Google Scholar
  20. Gong Y, Huang ZB, Christensen E, Gluud C (2008): Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008; Cd000551Google Scholar
  21. Halm U, Löser C, Löhr M, Katschinski M, Mössner J (1999) A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 13:951–957PubMedCrossRefGoogle Scholar
  22. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH (2004) Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127:723–729PubMedCrossRefGoogle Scholar
  23. Hellers G, Cortot A, Jewell D, Leijonmarck CE, Löfberg R, Malchow H, Nilsson LG, Pallone F, Pena S, Persson T, Prantera C, Rutgeerts P (1999) Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology 116:294–300PubMedCrossRefGoogle Scholar
  24. Hoffmeister A, Mayerle J, Beglinger C, Büchler MW, Bufler P, Dathe K, Fölsch UR, Friess H, Izbicki J, Kahl S, Klar E, Keller J, Knoefel WT, Layer P, Loehr M, Meier R, Riemann JF, Rünzi M, Schmid RM, Schreyer A, Tribl B, Werner J, Witt H, Mössner J, Lerch MM (2012) S3-Leitlinie Chronische Pankreatitis: Definition, Ätiologie, Diagnostik, konservative, interventionell endoskopische und operative Therapie der chronischen Pankreatitis. Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrank-heiten (DGVS). Z Gastroenterol 50:1176–1224PubMedCrossRefGoogle Scholar
  25. Kark W, Krebs-Richter H, Hotz J (1995) Improving the effect of orthograde colonic lavage with golytely solution by adding dimethicone. Z Gastroenterol 33:20–23PubMedGoogle Scholar
  26. Kassenärztliche B (2011): Verordnungsfähigkeit von Resolor®. Informationen für die Pharmakotherapieberater der KVen. Schreiben vom 11. Februar 2011Google Scholar
  27. Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL (2014) Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 40:123–132PubMedCrossRefGoogle Scholar
  28. Koop H, Schepp W, Muller-Lissner S, Madisch A, Micklefield G, Messmann H, Fuchs KH, Hotz J (2005) Gastroösophageale Refluxkrankheit - Ergebnisse einer evidenzbasierten Konsen-suskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 43:165–194CrossRefGoogle Scholar
  29. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623PubMedCentralPubMedCrossRefGoogle Scholar
  30. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Naucler E, Adler J, Eklund S (2005) Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 22:803–811PubMedCrossRefGoogle Scholar
  31. Labenz J, Tillenburg B, Peitz U, Köhl H, Becker T, Stolte M, Börsch G (1996) Ulcusheilung durch Helicobacter-pylori-Eradikation: Genügt eine Woche Therapie? Dtsch Med Wochenschr 121:3–8PubMedCrossRefGoogle Scholar
  32. Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310:2435–1542PubMedCrossRefGoogle Scholar
  33. Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M, Enck P, Frieling T, Haag S, Holtmann G, Karaus M, Kathemann S, Keller J, Kuhlbusch-Zicklam R, Kruis W, Langhorst J, Matthes H, Mönnikes H, Müller-Lissner S, Musial F, Otto B, Rosenberger C, Schemann M, van der Voort I, Dathe K, Preiss JC (2011) S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 49:237–293PubMedCrossRefGoogle Scholar
  34. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL (2004) Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20:1253–1269PubMedCrossRefGoogle Scholar
  35. Lind T, Mégraud F, Unge P, Bayerdörffer E, O‘Morain C, Spiller R, van Zenten S et al (1999) The MACH 2 study: Role of omeprazole in eradication of Helicobacter pylori with I-week triple therapies. Gastroenterology 116:248–253PubMedCrossRefGoogle Scholar
  36. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772–781PubMedCentralPubMedCrossRefGoogle Scholar
  37. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group (2011) Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet 377:905–913CrossRefGoogle Scholar
  38. Malfertheiner P1, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group (2012) Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut 61:646–664CrossRefGoogle Scholar
  39. Metcalf TJ, Irons TG, Sher LD, Young PC (1994) Simethicone in the treatment of infant colic: a randomized placebo-controlled multicenter trial. Pediatrics 94:29–34PubMedGoogle Scholar
  40. Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Haferland C, Bästlein E, Jebens C, Zekorn C, Knoth H, Stolte M, Lehn N (2008) One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 13:69–74PubMedCrossRefGoogle Scholar
  41. Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A (2011) Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 16:420–426PubMedCrossRefGoogle Scholar
  42. National Institute for Clinical Excellence (2004): Dyspepsia: management of dyspepsia in adults in primary care. Clinical Guideline 17. Internet: www.nice.org.uk/page.aspx?o=CG017NICEguidelineGoogle Scholar
  43. National Institute for Health and Clinical Excellence (2008): Clinical practice guideline: Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. Internet: www.nice.org.uk/nicemedia/live/11927/39746/39746.pdfGoogle Scholar
  44. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146:392–400PubMedCrossRefGoogle Scholar
  45. Peura DA, Gudmundson J, Siepman N, Pilmer BL, Freston J (2007) Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 52:983–987PubMedCrossRefGoogle Scholar
  46. Poynard T, Regimbeau C, Benhamou Y (2001) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15:355–361PubMedCrossRefGoogle Scholar
  47. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007): Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45: 549–559Google Scholar
  48. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S (2010) Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 138:1286–1296PubMedCrossRefGoogle Scholar
  49. Schmieder G, Stankov G, Zerle G, Schinzel S, Brune K (1993) Observer-blind study with metamizole versus tramadol and butylscopolamine in acute biliary colic pain. Arzneim Forsch 43:1216–1221Google Scholar
  50. Siegmund E, Löhr JM, Schuff-Werner P (2004) Die diagnostische Validität nichtinvasiver Pankreasfunktionstests - Eine Metaanalyse. Z Gastroenterol 42:1117–1128PubMedCrossRefGoogle Scholar
  51. Sjöstedt S, Befrits R, Sylvan A, Harthon C, Jörgensen L, Carling L, Modin S, Stubberöd A, Toth E, Lind T (2005) Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 22:183–191PubMedCrossRefGoogle Scholar
  52. Smith DS, Ferris CD (2003) Current concepts in diabetic gastroparesis. Drugs 63:1339–1358PubMedCrossRefGoogle Scholar
  53. Stedman CA, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963–978PubMedCrossRefGoogle Scholar
  54. Sudduth RH, DeAngelis S, Sherman KE, McNally PR (1995) The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: a double-bind randomized study. Gastrointest Endosc 42:413–415PubMedCrossRefGoogle Scholar
  55. Szajewska H, Horvath A, Piwowarczyk A (2010): Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther32: 1069–1079Google Scholar
  56. Talley NJ (2003) Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 56:362–369PubMedCentralPubMedCrossRefGoogle Scholar
  57. Trépo C, Chan HL, Lok A (2014): Hepatitis B virus infection. Lancet Jun 18. pii: S0140-6736(14)60220–8. doi: 10.1016/S0140-6736(14)60220-8. [Epub ahead of print]Google Scholar
  58. Tromm A, Bunganic I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk Study Group (2011) Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 140:425–434PubMedCrossRefGoogle Scholar
  59. van Zanten SV, Armstrong D, Chiba N, Flook N, White RJ, Chakraborty B, Gasco A (2006) Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled „ENTER” trial. Am. J Gastroenterol 101: 2096–2106. Erratum in. Am J Gastroenterol 101:217–1Google Scholar
  60. Wolfe MM, Lichtenstein DR (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888–1899PubMedCrossRefGoogle Scholar
  61. Wolle K, Malfertheiner P (2007) Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol 21:315–324PubMedCrossRefGoogle Scholar
  62. Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY (2013): Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: A Meta-Analysis. Gastroenterol Res Pract 2013: 23696–3 doi: 10.1155/2013/236963. Epub 2013 Apr 3Google Scholar
  63. Wueppenhorst N, Stueger HP, Kist M, Glocker EO (2013): High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother. Mar 5 [Epub ahead of print]Google Scholar
  64. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D (2007) The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 56:1353–1357PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Joachim Mössner
    • 1
  1. 1.Medizinische Klinik und Poliklinik IIUniversität LeipzigLeipzig

Personalised recommendations